丙型肝炎病毒分片段抗体检测蛋白质芯片质控参比品的建立及质量验证

建立能同时检测丙型肝炎病毒(HCV)嵌合抗体、核心抗体和NS3、NS4、NS5抗体的蛋白质芯片质控参比品,对质控合格的芯片进行质量验证。用3种HCV EIA试剂分别检测从3家医院收集的丙型肝炎病毒感染患血清及其他非HCV感染患血清,从3种EIA试剂同时阴性或阳性的血样中挑取阳性和阴性血清,然后用RNA hyb PCR试剂进行检测,从中再选取部分样本用RIBA3．0进行检测,确定HCV分片段抗体检测蛋白质芯片质控参比品。经质检合格的芯片用中国药品生物制品检定所的HCV参比品进行检定。通过490例临床标本的检测对芯片的质量进行进一步的验证。从收集的240份丙型肝炎病毒感染患血清及其他非HCV感染患血清筛选出30份血样(15份阳性,15份阴性)作为HCV分片段抗体检测蛋白芯片质控参比品。中国药品生物制品检定所的80份HCV参比品检定结果表明,混合抗体阳性检出率为39／40,阴性符合率为40／40,总符合率为98．7％;核心抗体阳性检出率为27／40,阴性符合率为40／40;NS3抗体阳性检出率为26／40,阴性符合率为39／40;NS4抗体阳性检出率为19／40,阴性符合率为40／40;NS5抗体阳性检出率2／40,阴性符合率为40／40。490例临床标本的检测结果表明,对于194例HCV阳性标本,蛋白质芯片混合抗体与ELISA的符合率达99．5％,分片段抗体符合率达97．4％,两种方法检测结果不符的标本经RIBA试剂确认,蛋白质芯片与RIBA试剂的符合率高度一致。对于296例各种HCV抗体阴性标本,蛋白质芯片检测结果全部为阴性。以上结果表明,制备的丙型肝炎病毒分片段抗体检测蛋白质芯片质控参比品可用于芯片生产的质量控制,经质控合格的芯片符合国家标准的要求,可用于临床检测。     

血液中丙型肝炎病毒抗体的检测-对血液制品制备用原料血浆的有关问题

<正>有些国家已经介绍筛检献血员的丙型肝炎抗体以降低输血后肝炎传播的危险。1990年12月4日,在国家生物标准和检定研究所(National Instituteof Biological Standards and Control,NIBSC)的会议上讨论了由献血员或单采浆献血员获得大合并血浆生产血液制品的有关策略问题。在讨论对于血液制品如免疫球蛋白,凝血因子和白蛋白的影响问题前,对病毒的特性,疾病的流行病学和检测的     

丙型肝炎病毒中和抗体的研究进展

丙型肝炎病毒(HCV)感染在全球范围内流行,如何能够有效控制和阻断HCV的感染和传播成为研究热点。HCV借助其极高的变异率逃避机体的免疫监视,并通过多种机制得以侵入、繁殖,引发一系列病理改变。因此,在感染初期激发机体有效的体液免疫反应,产生强烈而又广泛的中和作用,对阻断入侵和感染至关重要。我们对HCV中和抗体的研究进展予以简要综述。     

丙型肝炎病毒疫苗的评价及研究进展

丙型肝炎病毒(hepatitis C virus,HCV)感染导致全球严重的疾病负担。虽然相关疾病的治疗药物已取得了突破性进展,但高昂的价格使得用药覆盖率成为难题。疫苗是控制HCV感染相关疾病的根本途径。现就HCV疫苗的评价及研究进展作一概述。     

重组丙型肝炎病毒核心蛋白的原核表达、纯化和抗体制备

本文旨在获得纯化丙型肝炎病毒(HCV)核心蛋白(HCV-C)及抗HCV-C多克隆抗体,为深入研究HCV-C与肝细胞相互作用的分子机制奠定基础。首先以HCV1b亚型HC-J4-91全基因组质粒为模板,聚合酶链反应(PCR)扩增HCV-C基因,构建重组质粒pQE31-HCV-C。融合蛋白经原核表达、纯化后,免疫BALB/c小鼠,制备抗HCV-C多克隆抗体。利用酶联免疫吸附试验(ELISA)检测抗体效价,蛋白免疫印迹(Westernblot)和间接免疫荧光染色鉴定抗体特异性。结果显示,表达HCV-C的原核表达质粒pQE31-HCV-C构建正确,获得相对分子质量约22000的纯化融合蛋白。ELISA检测重组蛋白免疫小鼠的抗血清效价达1:12800。结果显示,自制的抗HCV-C多克隆抗体能特异性识别HCV-C。本研究获得了纯度较好、原核表达的HCV-C,并成功制备了抗HCV-C多克隆抗体,为深入研究HCV-C的致病机制提供了有实用价值的研究工具。     

丙型肝炎病毒RNA和丙型肝炎病毒抗体在慢性丙型肝炎干扰素治…

干扰素是慢性丙型肝炎抗病毒治疗的首选药物。近年来,丙型肝炎病毒（ＨＣＶ）ＲＮＡ和抗－ＨＣＶ检测方法的建立为干扰素疗效监测提供了新的手段。本文就这方面的进展作简要综述。     

丙型肝炎病毒抗体化学发光免疫检测方法的建立及其临床应用简

目的：建立丙型肝炎病毒（rmv）抗体化学发光免疫检测方法,并分析其临床应用价值。方法：应用基因工程重组的HCV抗原包被微孔板,以辣根过氧化物酶标记的羊抗人IgG为二抗,并结合鲁米诺化学发光底物系统,建立HCV抗体化学发光免疫检测方法;应用HCV抗体诊断试剂国家参考品分析所建立方法的特异性、灵敏度、稳定性和精密性,并-9北京万泰公司的ELISA试剂盒同时检测临床血清样本350份,比较检测结果。结果：检测结果符合国家参考品质量标准。批内变异系数5．1％。6．6％,批间变异系数9-5％;试剂盒置37℃考核3d,其稳定性良好;与万泰公司的ELISA检测结果对照,阳性符合率分别为99．0％,阴性符合率分别为100％,总符合率为99．4％;Kappa值为0．986,一致性强度最强。结论：建立了特异、敏感和稳定的HCV抗体化学发光免疫检测方法,适用于HCV感染的批量筛查,具有较大的临床应用价值。     

新发现的丙型肝炎病毒核心蛋白

近年来,有关新的丙型肝炎病毒核心基因及其编码产物的研究时有报道.与丙型肝炎病毒传统单一阅读框架翻译的病毒蛋白不同,新的核心C蛋白是由该病毒核心蛋白基因阅读框架序列+1移位后翻译产生的.新型C蛋白普遍存在于各个丙型肝炎病毒基因型中,约40%及 20%病毒感染者体内可检测到针对新型C蛋白的抗体和细胞免疫反应.在丙型肝炎病毒感染所致的肝癌患者中,新型C蛋白的表达量增高.新型C蛋白被认为可能与HCV感染慢性化和肝癌有关.     

抗丙肝病毒核心抗原单克隆抗体的研制与初步鉴定

用基因工程重组技术获得的丙肝病毒（ＨＣＶ）核心蛋白抗原与鼠血清白蛋白交联后免疫Ｂａｌｂ／ｃ小鼠,用杂交瘤技术成功地建立了４株稳定分泌抗核心抗原单克隆抗体的杂交瘤细胞,试验结果表明,该４株ＭｃＡｂｓ与免疫抗原及核心区Ｃ３３肽、ＣＰ９、ＣＰ１０抗原有较强的抗原－抗体反应,与ＨＣＶ ＮＳ３、ＮＳ４、ＮＳ５无反应,在竞争ＥＬＩＳＡ中,对ＨＣＶ－ＩｇＧ阳性血清有较好的抑制作用。４株ＭｃＡｂｓ中３株为ＩｇＧ２     

Follow-Up Study of Hypervariable Region Sequences of the Hepatitis C Virus (HCV) Genome in an Infant with Delayed Anti-HCV Antibody Responses

An infant born prematurely and infected with hepatitis C virus (HCV) one month after birth was followed for 4.5 years. The patient did not produce detectable anti-HCV antibodies until two years after the onset of hepatitis. Before seroconversion, a single clone of HCV, as determined by quasispecies of the hypervariable region (HVR) of the HCV genome, was almost exclusively found in the serum. After seroconversion, however, another distinct lineage of HCV clones replaced it within half a year. As HCV infection persisted further in the presence of anti-HCV antibodies, many derivatives of both sequence lineages emerged to exhibit the typical quasispecies feature of HVR sequences. Neither seroconversion nor the changes in HVR sequences influenced the serum aminotransferase titers.     

HCV全长NS3基因表达及在抗体检测中的应用

丙型肝炎病毒 (ＨＣＶ)是引起非甲非乙型肝炎的主要病原因子。被ＨＣＶ感染的病例中 ,超过 5 0 %以上会引起持续性感染、慢性肝炎 ,最终可能引起肝硬化和肝细胞癌[1] 。ＨＣＶ严重威胁人类健康 ,但目前对丙肝患者尚缺乏有效的治疗手段 ,因此 ,严格把好血源关 ,提高对丙肝患者检出的灵敏度 ,是阻止丙肝血源传播的有效手段。丙型肝炎病毒基因组为单股正链ＲＮＡ ,核苷酸长约 9.5ｋｂ ,仅含一个开放阅读框 ,翻译成一个大的聚蛋白前体 ,由宿主细胞信号肽酶和病毒蛋白酶加工成多个成熟蛋白。其中非结构蛋白ＮＳ3分子量为 70ｋＤ ,有丝氨酸蛋白酶…     

HCV Antibody Response and Genotype Distribution in Different Areas and Races of China

Hepatitis C virus (HCV) heterogeneity accounts for the failure of effective vaccine development and the lack of successful anti-viral therapy in some patients. Little is known about the immune response to HCV peptides and the region or race specific genotypes in China. The objective of this study was to characterize HCV antibody immune response to HCV peptides and HCV genotypes in different regions and races of China. A total of 363 serum samples were collected from HCV carriers in 6 regions in China. The immune response to HCV peptides was evaluated by ELISA. HCV genotypes were examined using nested RT-PCR. We found that the anti-HCV antibody neutralization rates were significantly different among the serum samples from different areas or from different races in the same area. For samples from Tibet and Sinkiang, the rates of neutralization by HCV peptides were only 3.2% and 30.8%, respectively. The genotypes of samples from Tibet and Sinkiang were apparently heterogeneic and included type I, II, III and multiple types (I/II/III, I/II, I/III, II/III). One specific sample with multiple-genotype (I/II/III) HCV infection was found to consist of type I, II, III, II/III and an unclassified genotype. These studies indicate that the anti-HCV antibody immune response to HCV peptides varied across regions and among races. The distribution of HCV genotypes among Tibetans in Tibet and Uighurs in Sinkiang was different from that in the inner areas of China. In addition, a “master” genotype, type II, was found to exist in HCV infection with multiple HCV genotypes.     

HCVRNA反转录PCR技术的建立及对血液样品的检测

实验建立了ＨＣＶ　ＲＮＡ的反转录和套式ＰＣＲ技术,扩增出２３２ｂｐ的核酸片段,经酶切电泳图谱和Ｓｏｕｔｈｅｒｎ杂交鉴定,来自ＨＣＶ基因５,端非编码区。实验从抗ＨＣＶ阳性的１８例血浆样品和１９例血清样品中分别检出７例和１３例ＨＣＶＲＮＡ阳性。     

丙型肝炎病毒受体研究进展

丙型肝炎病毒(HCV)入侵宿主细胞是在多种受体联合介导下才能完成的复杂过程.我们针对已报道的HCV 可能的细胞受体 CD81、低密度脂蛋白受体、B 族Ⅰ型清道夫受体、紧密连接蛋白家族、表皮生长子受体、酪氨酸激酶 EphA2受体、NPC1L1受体展开介绍,为今后研究和探索新型 HCV 疫苗和药物奠定基础.     

HO-1与HCV的相关性研究

血红素加氧酶-1（hemeoxygenase-1,HO-1）在肝脏和脾脏高表达,可以被包括某些病毒感染在内的多种因素诱导表达,具有抗氧化、抗炎、抗凋亡等保护作用。丙型肝炎病毒（hepatitisCvirus,HCV）感染可以造成慢型肝炎、肝硬化和肝癌等疾病,对人类健康造成很大威胁。研究发现HO-1通过影响HCV的复制发挥其保护作用,同时HCV也可以反向调控HO-1的表达。尽管HO-1与HCV相互作用的分子机制还不明确,但H0—1与HCV感染相关性研究不断取得重大进展,将为HCV感染的治疗提供一种新方法。     

Relation between Reactivity to the NS-4 Region Peptides of Hepatitis C Virus (HCV) and Clinical Features among Patients Infected with HCV Genotype 1b

Nearly all patients infected with hepatitis C virus (HCV) genotype 1b have reactivity to the core (c22-3) or non-structural (NS)-3 region (c33c) protein in a second-generation recombinant immunoblot assay (RIBA-2). However, reactivities to the NS-4 region antigens (5-1-1, c100-3) vary among patients. To clarify whether differences in serological reactivities to the NS-4 antigens are associated with the clinical features or response to interferon (IFN) therapy of patients infected with hepatitis C virus (HCV) genotype 1b, we clinically investigated 115 such patients. Positive reactions to 5-1-1 and c100-3 were seen in 75.7 and 79.1%, respectively, of the patients. There were no differences between the patients with and those without antibodies to NS-4 region antigens (5-1-1, c100-3) with regard to age, duration of HCV infection, severity of liver disease and virus load. Fifty-one of the patients were treated with recombinant IFN-α, and 17 of the 51 patients showed sustained response to the therapy. The sustained response was more frequently seen in the patients positive for antibodies to both 5-1-1 and c100-3 as compared with those negative for either or both antibodies (41.0% vs. 8.3%, P < 0.05).